Virtual Library
Start Your Search
A. Fukuda
Author of
-
+
P2.07 - Immunology and Immunotherapy (ID 708)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.07-031 - Relationship between Clinical Factors and the Expression of Programmed Death Ligand 1 in Lung Cancer (ID 9206)
09:30 - 09:30 | Author(s): A. Fukuda
- Abstract
Background:
Immune checkpoint inhibitors have progressed a new treatment option in non-small cell lung cancer. The tumor proportion score (TPS) of programmed death ligand 1 (PD-L1) is a predictive biomarker for determining the efficacy of treatment by immune checkpoint inhibitors. However, the relationship between clinical factors and the TPS is not well understood.
Method:
We retrospectively investigated patients whose samples were submitted for TPS evaluation from January 2017 to May 2017 and compared a TPS of 0% with a TPS of over 1% to identify the correlation between clinical factors and the TPS.
Result:
A total of 86 patients had samples evaluated for the TPS within study period. PD-L1 IHC testing was performed using a PD-L1 IHC 22C3 pharmDx kit for all samples. Two samples were determined to be unsuitable. Age, sex, tissue type, smoking history, performance status, stage, and gene mutation status were investigated as clinical factors. The diagnostic procedure, biopsied organ, tissue, or stored samples were investigated for their association with the TPS. The chi-square test was performed for the univariate analysis of all these factors. There was a significant difference in a TPS of 0% and a TPS of more than 1% in patients with ADC (P = 0.0339, odds ratio: 0.352, 95% CI: 0.0427–0.959) and an EGFR mutation (P = 0.0417, odds ratio: 0.427, 95% CI: 0.250–0.729). In addition, female sex tended to be associated with a TPS of 0% (P = 0.0526, odds ratio: 0.575, 95% CI: 0.335–0.986). However, SCC (P = 0.0113, odds ratio: 0.288, 95% CI: 0.0745–0.802), TBLB (p = 0.0278, odds ratio: 0.288, 95% CI: 0.0873–0.0951), and EBUS-TBNA (P = 0.0161, odds ratio and 95% CI: not applicable) were identified as factors associated with a TPS of over 1% in the same statistical analysis. Lymph node biopsy tended to be associated with a TPS of over 1% (P = 0.0643, odds ratio: 0.263, 95% CI: 0.0543–1.28).
Conclusion:
Adenocarcinoma and EGFR mutations are associated with a TPS of 0%, and squamous cell carcinoma is associated with a TPS of over 1%.
